Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.

PubWeight™: 2.11‹?› | Rank: Top 2%

🔗 View Article (PMID 11493442)

Published in Blood on August 15, 2001

Authors

M Stetler-Stevenson1, D C Arthur, N Jabbour, X Y Xie, J Molldrem, A J Barrett, D Venzon, M E Rick

Author Affiliations

1: Laboratory of Pathology and the Biostatistics, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. stetler@box-s.nih.gov

Articles citing this

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia (2012) 1.93

Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica (2011) 1.89

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica (2012) 1.18

Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica (2009) 1.16

Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica (2008) 1.05

Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia (2014) 1.02

Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes. Haematologica (2012) 0.86

Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica (2015) 0.85

Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery. J Hematol Oncol (2014) 0.85

Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am (2010) 0.83

Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome. Haematologica (2009) 0.81

Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica (2009) 0.81

Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. Haematologica (2014) 0.81

Utility of peripheral blood flow cytometry in differentiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias. Int J Clin Exp Pathol (2012) 0.80

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica (2016) 0.79

Flow cytometric immunophenotyping: emerging as an important diagnostic tool in the evaluation of cytopenic patients. Leuk Res (2009) 0.79

Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics. Haematologica (2012) 0.78

Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? Blood Rev (2012) 0.78

Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes. PLoS One (2014) 0.77

The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure. Oncologist (2014) 0.77

Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. Front Oncol (2016) 0.75

Differential surface expression of CD18 and CD44 by neutrophils in bone marrow and spleen contributed to the neutrophilia in thalidomide-treated female B6C3F1 mice. Toxicol Appl Pharmacol (2006) 0.75

Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood (2002) 0.75

Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. Mediterr J Hematol Infect Dis (2017) 0.75

Decreased CD10 Expression in the Bone Marrow Neutrophils of HIV Positive Patients. Mediterr J Hematol Infect Dis (2010) 0.75

Correlation Between Bone Marrow Blasts Counts With Flow Cytometry and Morphological Analysis in Myelodysplastic Syndromes. Ann Lab Med (2017) 0.75

Articles by these authors

(truncated to the top 100)

Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta (1986) 13.69

A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res (1982) 7.12

Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol (1981) 6.84

The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J (1973) 5.99

Evolutionary families of peptidases. Biochem J (1993) 5.81

L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J (1982) 5.67

Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99

A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood (2001) 4.19

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11

Human cathepsin B1. Purification and some properties of the enzyme. Biochem J (1973) 4.06

von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia (2008) 3.83

The electrophoretically 'slow' and 'fast' forms of the alpha 2-macroglobulin molecule. Biochem J (1979) 3.58

Evolutionary families of metallopeptidases. Methods Enzymol (1995) 3.48

Management of duodenal perforation after endoscopic retrograde cholangiopancreatography and sphincterotomy. Ann Surg (2000) 3.42

A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen. Anal Biochem (1979) 3.17

Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg (1983) 3.15

Cathepsin D. Purification of isoenzymes from human and chicken liver. Biochem J (1970) 3.09

Families of serine peptidases. Methods Enzymol (1994) 2.94

A new assay for cathepsin B1 and other thiol proteinases. Anal Biochem (1972) 2.93

Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75

High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol (2000) 2.65

Cathepsin B1. A lysosomal enzyme that degrades native collagen. Biochem J (1974) 2.65

Cathepsin D. Characteristics of immunoinhibition and the confirmation of a role in cartilage breakdown. Biochem J (1971) 2.60

MEROPS: the peptidase database. Nucleic Acids Res (1999) 2.60

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res (1998) 2.56

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood (2001) 2.52

Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet (1979) 2.48

Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant (2006) 2.47

An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature (1998) 2.44

Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum. Biochem J (1983) 2.42

Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood (1991) 2.35

Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood (1985) 2.35

Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med (2000) 2.33

Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res (1998) 2.33

Pectic polysaccharides of growing plant tissues. Biochem J (1967) 2.24

Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol (2008) 2.23

Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet (1981) 2.22

Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem J (1980) 2.20

Neutral proteinases of human spleen. Purification and criteria for homogeneity of elastase and cathepsin G. Biochem J (1976) 2.17

Human liver cathepsin L. Biochem J (1985) 2.16

Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol (2000) 2.15

Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood (1996) 2.12

Lysosomal acid proteinase of rabbit liver. Biochem J (1967) 2.12

The interaction of alpha2-macroglobulin with proteinases. Binding and inhibition of mammalian collagenases and other metal proteinases. Biochem J (1974) 2.11

Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 2.11

The inhibition of tissue acid proteinases by pepstatin. Biochem J (1972) 2.06

Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol (1997) 2.05

Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol (1996) 2.05

Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem (1986) 2.03

CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys (1992) 2.03

Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res (1996) 1.99

Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98

Hepatitis-associated aplastic anemia. N Engl J Med (1997) 1.98

Families of cysteine peptidases. Methods Enzymol (1994) 1.98

Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 1.95

Hypertension and convulsions in children receiving cyclosporin A. Lancet (1982) 1.89

Human cathepsin H. Biochem J (1980) 1.88

Management of symptomatic malignant melanoma of the gastrointestinal tract. Ann Surg Oncol (1999) 1.88

An improved color reagent for use in Barrett's assay of Cathepsin B. Anal Biochem (1976) 1.87

Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol (1999) 1.84

Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group). Cancer (1989) 1.82

A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med (1990) 1.81

Acute basophilic leukemia. A clinical, morphologic, and cytogenetic study of eight cases. Am J Clin Pathol (1991) 1.80

Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood (1996) 1.79

Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood (1994) 1.75

Action of rat liver cathepsin L on collagen and other substrates. Biochem J (1982) 1.73

Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood (1998) 1.73

Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood (1988) 1.72

Nomenclature and classification of the proteins homologous with the cysteine-proteinase inhibitor chicken cystatin. Biochem J (1986) 1.71

HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol (1995) 1.71

Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys (1991) 1.70

Inhibition of cysteine proteinases and dipeptidyl peptidase I by egg-white cystatin. Biochem J (1984) 1.69

MEROPS: the peptidase database. Nucleic Acids Res (2000) 1.69

Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected]. Eur J Cancer (2005) 1.67

Human cathepsin G. Catalytic and immunological properties. Biochem J (1976) 1.65

The many forms and functions of cellular proteinases. Fed Proc (1980) 1.64

Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet (1983) 1.64

Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem (1997) 1.63

Chicken alpha2-proteinase inhibitor: a serum protein homologous with ovoinhibitor of egg white. Biochim Biophys Acta (1974) 1.63

Possible lysosomal activation of pancreatic zymogens. Activation of both human trypsinogens by cathepsin B and spontaneous acid. Activation of human trypsinogen 1. Biol Chem Hoppe Seyler (1988) 1.63

The degradation of cartilage proteoglycans by tissue proteinases. Proteoglycan structure and its susceptibility to proteolysis. Biochem J (1977) 1.63

Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood (1997) 1.63

Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin. J Biol Chem (1987) 1.61

Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab (2006) 1.60

Renal cell carcinoma metastatic to the pancreas: a single-institution series and review of the literature. Urology (2000) 1.59

Human lysosomal elastase. Catalytic and immunological properties. Biochem J (1976) 1.59

The degradation of articular collagen by neutrophil proteinases. Biochim Biophys Acta (1977) 1.59

Lysosomes. Essays Biochem (1976) 1.58

The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun (1984) 1.56

Alpha 2-macroglobulin. Methods Enzymol (1981) 1.55

Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl Surg (1999) 1.55

Expanding the donor kidney pool: utility of renal allografts procured in a setting of uncontrolled cardiac death. Am J Transplant (2006) 1.53

Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys (1991) 1.53

Human plasma kallikrein. A rapid purification method with high yield. Biochem J (1981) 1.53

Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences--a Children's Cancer Group study. Genes Chromosomes Cancer (1999) 1.53

Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J Biol Chem (1999) 1.52

Degradation of fructose-1,6-bisphosphate aldolase by cathepsin B. Biochem J (1980) 1.52

Lysis and killing of bacteria by lysosomal proteinases. Infect Immun (1976) 1.50

Calpain inhibition by peptide epoxides. Biochem J (1985) 1.49